By the conclusion of this video, you'll be able to both
list and describe types of preclinical
toxicology studies that are performed for drug
candidates that have advanced to Phase 2 and Phase
3 clinical trials. Here is a graphic
that we have seen in an earlier video
in this course. Note that the pre-clinical
safety studies are not limited to the discovery period
of new drug development. Pre-clinical safety toxicology
studies continue even as a molecule has progressed into Phase 2 and Phase
3 clinical trials. These are conducted
in parallel with clinical trials that monitor safety and efficacy in humans. Let's highlight a few
selected examples of those later pre-clinical
safety studies. As drug candidates progress
through clinical trials, GLP toxicology studies of longer duration are
typically required. The duration of these
studies is based on the anticipated duration of
dosing in human subjects. An additional consideration is the expected duration of the treatment once
the drug is approved. The guidelines shown in this table differ
somewhat from those for the GLP toxicology
coverage of clinical trials, although following
the ladder will often satisfy both requirements. Nonetheless, the drug
hunting team must ensure both sets of guidelines
are carefully considered. Another type of
safety assessment performed while the
drug is in the clinic, are the reproductive
toxicology studies. There are three types
of these studies. One fertility, two embryo
fetal development, and three, pre and
postnatal development. These reproductive
toxicology studies, are typically conducting using rodents such as rats and mice. However, regulations require the embryo fetal
development study also include a non rodent
species, typically the rabbit. For the fertility studies, male and female
non-pregnant rodents are administered to the
drug prior to mating, during mating, and
up to implantation. In the embryo fetal
development studies, pregnant animals are
administered to drug from implantation to closure
of the hard palate. In other words, during the
period of organogenesis, and the fetuses are evaluated at the end of gestation
for external, visceral, and skeletal
abnormalities. For the pre and postnatal
development study, pregnant females are
administered to drug from implantation through
gestation and lactation. The offspring are
monitored for viability, growth, and development, including learning and
behavior continuing through sexual development and may
include a mating phase. All three studies are
critical as clinical trials progressing recruit a
broader pool of patients. In particular, the embryo fetal development
toxicity studies are important for informing women of child-bearing
potential, of the potential risks of
using the drug while pregnant. Finally, long-term
carcinogenicity studies are often required
for drug approval. These studies are typically
performed in two species, the rat and mouse. These are lifetime
studies and are approximately two years long. More recently, transgenic
mice are commonly used and this study only
takes about six months. Throughout the
carcinogenicity study, the animals are dosed
with a compound and observed for tumor
development and progression. Carcinogenicity studies
are not required for all molecules
in clinical trials. If the indication
does not require that the drug be taken for
extended periods, for example, as
with an antibiotic, then carcinogenicity testing
will not be necessary. These studies are
also not typically required for oncology
indications, and less life expectancy is anticipated to be greater
than or equal to five years. In this case, adjuvant
therapies administered during this time generally require a carcinogenicity
study be performed. For clinical indications where chronic drug administration
will be required, additional toxicology
studies evaluate long-term safety of the drug, as well as reproductive
and carcinogenicity risks. These studies fall
under the umbrella of pre-clinical safety testing, but they are actually
performed after a molecule has advanced to
later stage clinical trials